Best Net Terms Solutions for Pharmaceutical Manufacturing

The pharmaceutical industry faces extraordinary financial complexity, with a gross-to-net (GTN) drag reaching approximately $335 billion annually and extended payment terms that often stretch 60-90 days—creating significant cash flow challenges for manufacturers. With the Inflation Reduction Act (IRA) adding new compliance requirements and pricing pressures, pharmaceutical companies need specialized net terms solutions that address their unique operational and regulatory environment. For manufacturers seeking to offer competitive payment terms while protecting cash flow and managing credit risk, Resolve's B2B Net Terms platform provides a comprehensive solution designed specifically for these industry challenges.

Key Takeaways

• Pharmaceutical manufacturers face an approximately $335 billion GTN bubble requiring specialized financial solutions that address complex rebates, chargebacks, and government pricing programs
• Non-recourse financing solutions eliminate credit risk while providing immediate funding, addressing the industry's extended payment cycles that can stretch 60-90 days
• AI-powered platforms deliver instant credit decisions and automated AR workflows, reducing manual processing for complex pharmaceutical invoices
• GTN optimization platforms address strategic financial forecasting needs, while payment platforms handle execution and financing
• Industry-specific solutions offer specialized features like pharma ERP integrations, chargeback defense, and regulatory compliance documentation
• Pharmaceutical manufacturers must choose between financing-enabled platforms (providing capital) and software-only solutions (requiring internal capital) based on their working capital needs

1. Resolve Pay – AI-Powered Non-Recourse Net Terms Financing

Resolve Pay offers pharmaceutical manufacturers a unique advantage: 100% non-recourse financing that eliminates credit risk while providing instant approvals and 24-hour funding. Unlike traditional factoring, Resolve takes on the credit assessment, credit decision, and majority risk of late payments or defaults, allowing pharma companies to offer net terms without jeopardizing cash flow.

Best For

Pharmaceutical manufacturers need to offer net terms without credit risk, with instant approvals supporting high-value B2B transactions.

Key Features

• 100% non-recourse financing eliminates merchant credit risk completely
• AI-powered instant credit decisions with up to 90% invoice advance
• Enterprise ERP integration supporting NetSuite, QuickBooks, and SAP
• Automated AR workflow with payment reminders and collections management
• 24-hour funding cycles that address extended payment term challenges
• Seamless integration with AI-Powered Automation

Pharmaceutical Relevance

Resolve's platform directly addresses the pharmaceutical industry's extended payment cycle challenges. With nearly 50% of B2B invoices paid late, pharmaceutical manufacturers face significant working capital constraints when offering the net 60-90 day terms that buyers expect. Resolve's ability to advance up to 90% of invoice value within 24 hours while assuming credit risk enables manufacturers to maintain healthy cash flow while remaining competitive.

The non-recourse nature means pharmaceutical manufacturers can confidently offer flexible credit terms to build relationships with healthcare providers, hospitals, and distributors without worrying about default risk. This is particularly valuable in an industry where building long-term partnerships often requires accommodating extended payment terms.

Customer Validation

"Resolve has positively impacted our cash flow. Their advance on each invoice we submit has translated into quicker receivables, directly contributing to healthier cash flow management," shared a satisfied client.

Resolve's AI-powered underwriting provides credit decisions 9x faster than traditional methods, enabling pharmaceutical manufacturers to respond quickly to customer orders while the platform's automated collections management reduces administrative burden on AR teams.

2. IQVIA Orchestrated Gross-to-Net

IQVIA's Orchestrated Gross-to-Net platform addresses the strategic layer of pharmaceutical financial complexity, providing comprehensive GTN optimization specifically designed for the life sciences industry. With GTN drag for brand-name drugs reaching about $335 billion in 2023, IQVIA's platform helps manufacturers navigate the "new margin era" where profit margins are shrinking due to policy changes and payer pressures.

Pharmaceutical manufacturers needing strategic GTN financial optimization and forecasting for complex rebate structures, chargebacks, and government pricing programs.

Key Features

• Smart, centralized financial optimization platform digitizing GTN processes
• GTN Data Hub integrating disparate data sources with secure, automated cloud-based tool
• Scenario modeling and optimization for contract-level forecasts with margin impact understanding
• IQVIA Connected Intelligence™ powering industry-leading GTN methodologies
• Dedicated Market Access Center of Excellence with pharmaceutical expertise

IQVIA's platform is built specifically for pharmaceutical market access departments managing the complex web of rebates, chargebacks, and government pricing programs that characterize the industry. With the IRA legislation requiring new compliance considerations and 10-15+ year forecasting horizons, IQVIA's strategic approach addresses the root causes of the approximately $335 billion GTN bubble.

3. IntegriChain ICyte Platform

IntegriChain offers a comprehensive data, consulting, and business process platform specifically designed for pharmaceutical market access departments. Their ICyte Platform unifies contracts & pricing, gross-to-net, channel, and patient services for complete therapy commercialization, addressing the multi-dimensional GTN forecasting required for IRA compliance.

Pharmaceutical and biotech companies needing a comprehensive commercialization platform with GTN/Net Revenue Management and IRA compliance capabilities.

Key Features

• Platform-based application suites covering multiple facets of Net Revenue Management
• Unifies contracts & pricing, gross-to-net, channel, and patient services
• Advisory services providing expert policy, pricing, reimbursement, and regulatory guidance
• Revenue Analytics Collaborative (RAC) with 850+ industry colleagues from 275+ manufacturers
• Multi-dimensional GTN forecasting with 10-15+ year horizons for IRA compliance

IntegriChain addresses the pharmaceutical industry's challenge of navigating the complex regulatory and pricing landscape while maintaining profitability. Their platform facilitates collaboration across market access, finance, and business teams using established frameworks to ensure alignment on net revenue optimization strategies. With expert consultants who have 25+ years of pharma/biotech experience, IntegriChain provides both the technology platform and strategic guidance needed to address the approximately $335 billion GTN bubble effectively.

4.  TreviPay

TreviPay leverages 40+ years of B2B payment experience and powers more than $8 billion in global trade across 32 countries. The platform offers enterprise-grade net terms solutions with documented success in healthcare verticals.

Enterprise pharmaceutical manufacturers needing complex multi-entity support with optional funded models and global payment capabilities.

Key Features

• Powers more than $8 billion in annual global trade volume
• Sub-30 second credit decisions with real-time fraud detection
• Omnichannel net terms across web, app, in-store, POS systems across 30+ countries
• Optional funded model providing guaranteed settlement (credit risk transfer)
• Partnership with Mastercard for B2B payment capabilities across EMEA markets

TreviPay's enterprise scale and healthcare vertical expertise make it valuable for large pharmaceutical manufacturers with complex global operations. Their published results—including up to 90% fewer invoicing errors, a 98% reduction in DSO, and 100%+ higher average order volume—demonstrate the kind of impact TreviPay aims to deliver in complex B2B environments.

5. HighRadius

HighRadius offers autonomous AR automation software with a pharmaceutical customer base of 50+ companies, including major players like Sanofi and Johnson & Johnson Consumer. Their platform delivers high automation rates, with Sanofi achieving 94% automatic payment posting and J&J Consumer reaching 95% automated posting with a 43% reduction in DDO.

Large pharmaceutical enterprises with dedicated finance teams wanting software-only AR automation while maintaining internal control over processes.

Key Features

• 95% straight-through cash posting and automated deductions coding
• 100% automated remittance aggregation from checks, emails, and portals
• AI-Based Dispute Validity Predictor for prioritized deductions resolution
• Comprehensive AR spectrum coverage: credit management, collections, deductions, cash application
• Pharmaceutical customer base with documented case studies

HighRadius addresses the pharmaceutical industry's complex deductions and chargeback management needs through specialized automation. Their software-only approach allows enterprises to maintain control over AR processes while leveraging advanced AI technology to reduce manual intervention and accelerate cash flow. The platform's comprehensive coverage of the entire AR spectrum—from credit management through cash application—provides pharmaceutical manufacturers with end-to-end automation that handles the industry's unique challenges, including complex rebate structures and regulatory compliance requirements.

6. Billtrust

Billtrust processes $1+ trillion annually with 24+ years of AR automation experience, offering proven success in healthcare and life sciences. Their platform combines digital lockbox technology with AI-powered cash application that achieves industry-leading match rates, significantly reducing manual reconciliation for complex pharmaceutical invoices.

Pharmaceutical manufacturers and distributors with complex AR needs requiring established, proven automation with healthcare experience.

Key Features

• AI-powered cash application with industry-leading match rates
• Digital Lockbox for automated virtual card processing
• Integration with 260+ accounts payable portals used by healthcare buyers
• Healthcare companies adopting AR automation report faster cash flow
• Healthcare organizations reduce DSO by an average of 12 days with AR automation

Healthcare industry data shows that AR automation delivers tangible results: 12-day DSO reduction on average and 7-day improvement in Days to Pay (DTP), with 55% of health and life sciences companies successfully moving from print to digital invoicing.

7. Curbstone

Curbstone is built specifically for pharmaceutical distribution, featuring native integration with Iptor Pharma ERP and addressing the industry's substantial chargeback challenges. As a PCI-validated Level 1 Service Provider with remote tokenization, Curbstone ensures compliance with the strictest pharmaceutical security requirements.

Pharmaceutical manufacturers and distributors using Iptor Pharma ERP or experiencing significant chargeback and rebate abuse issues.

Key Features

• Native integration with Iptor Pharma ERP (out-of-the-box solution)
• Chargeback defense system addressing rebate abuse and fraud
• IBM i/AS400 real-time integration for pharmaceutical distribution
• PCI-validated Level 1 Service Provider with remote tokenization
• Integration with DPS, HarrisData, Infor XA, and other pharma distribution systems

The pharmaceutical industry faces significant annual losses to chargebacks and rebate abuse, making Curbstone's specialized protection particularly valuable. Their native Iptor Pharma ERP integration eliminates the need for custom development, which is especially beneficial for manufacturers already using this industry-specific ERP system that's widely adopted in pharmaceutical distribution.

8. Versapay

Versapay processes over $260 billion annually with 10,000+ customers and 120M+ transactions, offering a collaborative AR automation platform that emphasizes customer communication and relationship management. Their PayFac status ensures faster onboarding for complex pharmaceutical use cases.

Pharmaceutical companies seeking collaborative AR automation with strong customer communication capabilities and healthcare experience.

Key Features

• Collaborative AR network connecting finance teams directly with customers
• Unified platform for automation across invoice-to-cash: invoicing, collections, cash application, payments
• Self-service customer portal with multiple payment methods and recurring payment scheduling
• PayFac status enabling fast onboarding for complex use cases
• Processes over $260 billion annually demonstrating enterprise-grade scale

Versapay's collaborative approach is particularly valuable for pharmaceutical manufacturers who need to maintain strong relationships with healthcare providers, hospitals, and distributors while streamlining AR processes. The platform's unified coverage of the entire invoice-to-cash cycle ensures that pharmaceutical companies can manage all aspects of their receivables through a single solution.

Choosing the Right Net Terms Solution for Your Pharmaceutical Business

Selecting the right net terms solution for pharmaceutical manufacturing requires careful evaluation of your specific operational needs, financial constraints, and strategic objectives. The pharmaceutical industry's unique challenges—including the approximately $335 billion GTN bubble, extended payment terms of 60-90 days, strict regulatory compliance, and complex global supply chains—demand solutions purpose-built for these requirements.

For pharmaceutical manufacturers seeking to eliminate credit risk while maintaining healthy cash flow, Resolve Pay's non-recourse financing model offers a compelling solution. The platform's ability to advance up to 90% of invoice value within 24 hours while assuming the credit risk enables manufacturers to offer competitive net terms without jeopardizing their financial position. This becomes particularly valuable when working with healthcare providers, hospitals, and distributors who expect flexible payment options.

Manufacturers facing complex GTN challenges should consider strategic platforms like IQVIA and IntegriChain that address the root causes of revenue leakage through comprehensive forecasting and optimization. Meanwhile, enterprises with strong internal capital positions might prefer software-only solutions like HighRadius or Billtrust that provide automation without external financing.

The instant credit approval capabilities powered by AI accelerate the order-to-cash cycle, enabling pharmaceutical manufacturers to respond quickly to customer orders without the multi-day delays typical of traditional credit evaluation processes. Combined with seamless ERP integration supporting NetSuite, QuickBooks, and SAP, the right net terms solution provides pharmaceutical manufacturers with strategic infrastructure that supports sustainable growth.

As the pharmaceutical market continues navigating the "new margin era" with IRA compliance requirements and pricing pressures, having a net terms solution that addresses both immediate cash flow needs and long-term strategic objectives becomes increasingly critical.

Why Resolve Pay is the Optimal Choice for Pharmaceutical Manufacturers

Among the net term solutions available to pharmaceutical manufacturers, Resolve Pay delivers a unique combination of risk elimination, rapid funding, and intelligent automation specifically designed for the industry's challenges. The platform's 100% non-recourse financing model means pharmaceutical manufacturers can extend competitive payment terms to healthcare providers, hospitals, and distributors without any credit risk exposure—a critical advantage when building long-term partnerships in an industry where relationships drive growth.

What sets Resolve apart is the integration of AI-powered credit decisions that provide instant approvals, eliminating the multi-day waiting periods that slow traditional financing. This speed is particularly valuable in pharmaceutical manufacturing, where order fulfillment timing can be critical for maintaining supply chains and customer relationships. The 24-hour funding cycle ensures that manufacturers receive cash flow when they need it, while customers maintain their preferred 60-90 day payment terms.

The platform's comprehensive approach addresses the entire credit-to-cash lifecycle through automated AR workflows, payment reminders, and collections management—reducing administrative burden on finance teams while maintaining professional customer relationships. With seamless integration into major ERP systems including NetSuite, QuickBooks, and SAP, Resolve Pay becomes part of your existing financial infrastructure rather than requiring disruptive process changes.

For pharmaceutical manufacturers navigating the approximately $335 billion GTN challenge, extended payment cycles, and increasing pricing pressures from the Inflation Reduction Act, Resolve Pay provides the financial flexibility and operational efficiency needed to compete effectively while protecting cash flow and eliminating credit risk.

Frequently Asked Questions

How can net terms solutions address the long payment cycles common in the pharmaceutical industry?

Platforms like Resolve Pay address the pharmaceutical industry's extended payment terms by advancing up to 90% of invoice value within 24 hours while customers maintain their standard 60-90 day payment terms. This non-recourse financing model eliminates the cash flow strain without requiring customers to change their payment behavior. The manufacturer receives immediate funding while the payment platform manages credit risk and collections.

What makes Resolve's net terms solution different from traditional factoring for pharmaceutical companies?

Resolve's non-recourse financing differs from traditional factoring in several key ways: it's truly non-recourse (what you get is always yours to keep), offers up to 90% advance rates, maintains your customer relationships through white-label experiences, and provides AI-powered instant credit decisions rather than lengthy manual underwriting. Unlike factoring, Resolve acts as your "credit team on tap" while you retain control of customer relationships.

How does AI improve credit decisions for B2B transactions in pharmaceutical manufacturing?

AI powers instant credit decisions that are 9x faster than traditional methods, automated cash application with high match rates, and intelligent risk assessment algorithms that evaluate thousands of data points. For pharmaceutical manufacturers, AI reduces manual processing of complex invoices and accelerates credit decisions from days to seconds. This automation enables faster order fulfillment and improved customer experience while reducing administrative overhead on AR teams.

Can net terms solutions integrate with existing ERP and accounting systems in the pharmaceutical industry?

Yes, leading net terms solutions offer native integrations with major ERP systems commonly used in pharmaceutical manufacturing, including NetSuite, SAP, QuickBooks, and industry-specific systems like Iptor Pharma. Resolve's integration platform fits directly into your B2B ecommerce and accounting stack—with instant plug-ins, flexible APIs, and automated syncing. These integrations enable automated invoice synchronization, real-time payment updates, and seamless financial reconciliation.

How quickly can my pharmaceutical business receive payments through Resolve's advance pay feature?

Resolve's advance pay feature provides funding within 24 hours of invoice approval, allowing pharmaceutical manufacturers to receive up to 90% of invoice value while customers maintain their standard payment terms. This immediate access to capital addresses the industry's extended payment cycles without requiring customers to change their payment behavior, effectively transforming the health of your business by accelerating cash flow.

This post is to be used for informational purposes only and does not constitute formal legal, business, or tax advice. Each person should consult his or her own attorney, business advisor, or tax advisor with respect to matters referenced in this post. Resolve assumes no liability for actions taken in reliance upon the information contained herein.